1st Quarter - Report

BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC for BOEHRINGER INGELHEIM USA CORPORATION

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$962,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 20, 2010 $962,000 Replaced
1st Quarter - Amendment Apr 20, 2011 $984,000 Yes

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Patent reform, Patent settlements; H.R. 1706 and S. 5369

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS LD, Rep. Artur Davis
CANDIE PHIPPS —
PAUL ROMNESS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 5369 (111th), H.R. 1706 (111th)

Health Issues HCR

Health care reform: America's Affordable Health Choices Act, HR 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S 1679: Senate HELP and S 1796: Senate Finance committee drafts); pricing/rebates, importation, coverage, comparative effectiveness, biosimilars, transparency; 340B pricing, Independent Patient Advisory Board; PPACA - Patient Protection and Affordable Care Act

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS LD, Rep. Artur Davis
CANDIE PHIPPS —
PAUL ROMNESS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3200 (111th)

Agriculture AGR

APHIS/CVB issues, veterinary labeling issues

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS LD, Rep. Artur Davis
CANDIE PHIPPS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Medicare Part D preservation in health reform Rebates, Miedicare, Medicaid and Medicaid Expansion in health reform 340B pricing

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS LD, Rep. Artur Davis

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Tariff (miscellaneous tariff bills) TAR

Miscellaneous Tariff Bill; relating to the duty suspension of cyclopropylaminonicotine acid

LobbyistCovered position, as disclosed
CANDIE PHIPPS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.